Peking University Emerges Victorious in 2024 ASC Student Supercomputer Challenge Finals
Business Wire
BEIJING--(BUSINESS WIRE)-- #ASC--Peking University Emerges Victorious in 2024 ASC Student Supercomputer Challenge Finals
Peking University
News and Video Search Results
News coverage
-
Global Times: Industrial sector leads growth in Q1, with high-tech manufacturing being a highlight
PR Newswire Asia
-
Point of convergence
PR Newswire Asia
-
Memory Of Rabindranath Tagore To Help Bridge Sino-India Gap – Analysis
Eurasia Review
-
Airdoc Technology (02251.HK) achieved remarkable success in 2023, accelerating its commercialization in an unparalleled way
EQS Group
0 shares
1 views
You might like
Peking University media coverage
The Second International Conference on Single-cell and Spatial Omics (TICSSO-2) : showcasing the state-of-the-art bioscience achievements
PR Newswire Asia
SHENZHEN, China, April 9, 2024 /PRNewswire/ -- The Second International Conference on Single-cell and Spatial Omics..
-
Focus Universal Inc. Announces Warren Wang as Chief Strategy Officer
Accesswire
-
Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer
GlobeNewswire
-
HUTCHMED Highlights Data to be Presented at AACR Congress 2024
GlobeNewswire
-
Harmonizing Cultures: Gen Z Explore the Universal Language of Music
PR Newswire Asia
Advertisement
More coverage
Airdoc Technology Unveils 2023 Financial Highlights, Revenue by 79%, Serving 6.83 Million cases
EQS Group
EQS Newswire / 02/04/2024 / 09:53 UTC+8Airdoc Technology Unveils 2023 Financial Highlights, Revenue by 79%, Serving 6.83 Million..
-
2024 China-ASEAN Youth Culture Week and the 7th China-ASEAN Youth Symposium Successfully HeldPressReleaseTMPZn1NeB.jpg
Media OutReach
-
Global Times: Xi's inspection tour highlights critical role, vast potential of China's central region
PR Newswire Asia
-
Revolutionizing Science and Technology Education: Top University Presidents Converge in Hong Kong
PR Newswire Asia
-
HUTCHMED Initiates Registration Stage of the ESLIM-02 Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China
GlobeNewswire